Orthocell Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Orthocell.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	16.1%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Oct 25

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

May 31

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Feb 15

How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?

Dec 24

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Orthocell has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

ASX:OCC - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	5	-7	-7	-7	N/A
9/30/2023	5	-7	3	4	N/A
6/30/2023	4	-6	14	15	N/A
3/31/2023	3	-7	14	14	N/A
12/31/2022	2	-9	13	14	N/A
9/30/2022	2	-9	3	4	N/A
6/30/2022	2	-9	-7	-6	N/A
3/31/2022	1	-9	-6	-6	N/A
12/31/2021	1	-9	-6	-6	N/A
9/30/2021	1	-9	-5	-5	N/A
6/30/2021	1	-9	-5	-5	N/A
3/31/2021	1	-9	-4	-4	N/A
12/31/2020	1	-8	-4	-4	N/A
9/30/2020	1	-7	-5	-5	N/A
6/30/2020	1	-6	-5	-5	N/A
3/31/2020	1	-6	-7	-6	N/A
12/31/2019	1	-7	-8	-8	N/A
9/30/2019	1	-6	-6	-6	N/A
6/30/2019	1	-6	-5	-4	N/A
3/31/2019	1	-6	-5	-4	N/A
12/31/2018	1	-6	-5	-4	N/A
9/30/2018	1	-6	-5	-4	N/A
6/30/2018	1	-6	-5	-5	N/A
3/31/2018	1	-4	-4	-3	N/A
12/31/2017	1	-2	-2	-2	N/A
9/30/2017	1	-3	N/A	-3	N/A
6/30/2017	1	-4	N/A	-4	N/A
3/31/2017	1	-4	N/A	-4	N/A
12/31/2016	1	-4	N/A	-4	N/A
9/30/2016	1	-4	N/A	-4	N/A
6/30/2016	1	-4	N/A	-3	N/A
3/31/2016	1	-4	N/A	-3	N/A
12/31/2015	1	-3	N/A	-3	N/A
9/30/2015	1	-4	N/A	-3	N/A
6/30/2015	1	-4	N/A	-3	N/A
3/31/2015	1	-4	N/A	-3	N/A
12/31/2014	1	-5	N/A	-4	N/A
9/30/2014	1	-3	N/A	-3	N/A
6/30/2014	1	-2	N/A	-2	N/A
3/31/2014	1	-2	N/A	-1	N/A
12/31/2013	1	-1	N/A	0	N/A
9/30/2013	1	-1	N/A	0	N/A
6/30/2013	1	-1	N/A	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if OCC's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if OCC's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if OCC's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if OCC's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if OCC's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if OCC's Return on Equity is forecast to be high in 3 years time

Orthocell Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023

Recent updates

Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 3.500001 million.

New minor risk - Shareholder dilution

Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.

Orthocell Limited Announces Resignation of Matthew Callahan from the Board

Orthocell Limited Announces Changes to its Board

Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Orthocell Limited Announces Board Changes

Less than half of directors are independent

Orthocell Limited Announces Board Changes

Orthocell Limited, Annual General Meeting, Oct 31, 2023

Full year 2023 earnings released: AU$0.032 loss per share (vs AU$0.047 loss in FY 2022)

New minor risk - Financial data availability

Orthocell Limited Appoints John Van Der Wielen as Independent Non-Executive Chairman, Effective 1 June 2023

First half 2023 earnings released: AU$0.021 loss per share (vs AU$0.024 loss in 1H 2022)

We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth

Less than half of directors are independent

Orthocell Limited's Rotator Cuff Study Success with Cross-Over Patients

Orthocell Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: AU$0.047 loss per share (vs AU$0.048 loss in FY 2021)

We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate

Orthocell Limited Announces the Completion of Its RemplirTM Nerve Reconstruction Study

Less than half of directors are independent

Orthocell (ASX:OCC) Is In A Good Position To Deliver On Growth Plans

Orthocell Ordinary Shares to Be Deleted from Other OTC

We're Not Worried About Orthocell's (ASX:OCC) Cash Burn

CEO, MD & Executive Director recently sold AU$552k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2021 earnings released: AU$0.047 loss per share (vs AU$0.036 loss in FY 2020)

Orthocell Limited Announces CelGro Nerve Study Results

Orthocell Limited Announces First Interim Data Read Out of All Patients in the Celgro® Nerve Regeneration Trial At 12 Months Post Treatment

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

Orthocell Limited Announces New Collagen Rope Patent for CelGro Platform Technology

Celgro Study Results Open Up New US Market Access Strategy

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Orthocell Limited Announces Publication of Successful Case Study Focussing on the Combination of Celgro® Collagen Medical Device and Autologous Tenocyte Implantation for the Surgical Repair of Large Degenerate Tear of the Gluteal Medius Tendo

Orthocell Ltd Receives US Market Clearance

Orthocell Limited Receives First US CelGro Product Approval

New 90-day high: AU$0.49

Orthocell Limited Receives Australian Market Approval for its Celgro, a Collagen Medical Device

How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?

New 90-day high: AU$0.46

Orthocell Limited Announces Patient Enrolment for the Celgro® Nerve Regeneration Trial Is Now Complete

New 90-day low: AU$0.33

Orthocell Limited Announces CelGro Bone Regeneration in Dental & Orthopedic Applications

Full year earnings released - AU$0.036 loss per share

New 90-day high - AU$0.43

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies